Hans Biomed

At a glance

Hans Biomed filed 42 disclosures in the last 12 months, including 18 5% holder, 1 insider, 1 buyback and 1 issuance. The most recent key filing was on Oct 2.

Revenue for 2025 was ₩89.8B, up 10.7% on 2024. It made an operating loss of ₩25.9B. Debt was 273% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩64.8B and operating profit of ₩6.5B.

The 2025 annual report lists 289 employees with an average tenure of 5.2 years and average pay of ₩41.5M, #1722 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩180.8M each on average. It paid no cash dividend for 2025. 황호찬 and related parties held 25.19% at year end.

From the 2025 annual report

Staff: 289 (133 men, 156 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩12B. Directors and auditors: 4, paid ₩723.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

황호찬 holds 23.95%; with 3 related parties the group holds 25.19% of common shares at year end.

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary